Wandercraft's Rehab Path Into Humanoids
Fourier
Wandercraft matters because it is not just another rehab device company, it is proving that rehab robots can be a real commercial wedge into broader humanoid robotics. Atalante X is already in more than 100 rehab centers, which means Wandercraft is collecting clinical data, therapist workflow knowledge, and walking control experience in live settings while also funding and training a parallel humanoid program called Calvin-40.
-
Atalante X is a hands free, self balancing gait robot, not a simple brace. Therapists configure sessions through Wandercraft software, then track usage, gait kinematics, and functional progress. That creates the kind of closed loop control and real world locomotion dataset that also matters for humanoids.
-
Wandercraft has paired that clinical footprint with fresh capital. Its June 2025 Series D brought total funding secured to $75M, earmarked for expanding Atalante X adoption and developing Calvin-40. That gives the humanoid effort a funded bridge from rehab revenue and clinical credibility into a larger robotics market.
-
The competitive overlap with Fourier is strategic, not just product level. Hocoma is a rehab incumbent and Ekso is a rehab specialist, but Wandercraft is one of the few companies turning gait rehabilitation into a training ground for full body mobile robots. If that playbook works, it makes rehab robotics look like a launchpad, not a niche endpoint.
The next phase is a race to turn rehab deployments into a broader robotics platform. Companies that can use clinics to refine balance, motion planning, and human safe operation will have a practical path into assistive and industrial humanoids. That raises the stakes in rehab from equipment sales to control system leadership.